Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Nestle's new Vital Pursuit brand targets individuals on weight-loss drugs without mentioning medications on packaging, addr...
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.
Trevena shares dropped 33.7% to $0.23 with a session volume of 23.65 million. Notably, TRV045 did not cause S1P1R desensitizati...
-Reuters
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market l...
Novartis has filed a lawsuit to block a Maryland law requiring drugmakers to offer discounts on drugs through third-party pharm...
Novartis reveals Phase 3 data confirming remibrutinib's long-term efficacy and safety for chronic spontaneous urticaria, sh...
https://www.novartis.com/news/media-releases/novartis-scemblix-phase-iii-data-first-show-superior-efficacy-favorable-safety-and...
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placeb...
